Chennai Petro reported a significant net loss of ₹633.7 crore for Q2 FY25, compared to a profit of ₹1,195 crore in the same period last year. The company's revenue dropped by 27% to ₹12,086.4 crore from ₹16,544.7 crore year-on-year. EBITDA showed a loss of ₹674.7 crore versus a positive EBITDA of ₹1,804.5 crore in the previous year, with a margin at 10.9%. Syngene International reported a net profit of ₹106.1 crore, slightly above the CNBC-TV18 poll estimate of ₹101 crore, with revenue at ₹891 crore, EBITDA at ₹245 crore, and a margin at 27.5%. Dr. Lal Path Labs posted a net profit of ₹130.8 crore, surpassing the poll estimate of ₹124.7 crore, with revenue at ₹660.2 crore, EBITDA at ₹202.5 crore, and a margin at 30.7%.